iiinova — where your digital self keeps evolving

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Influence of FLAIR Inclusion on Recurrence Patterns and Outcomes in Glioblastoma: Results from a Prospective Adaptive Radiotherapy Trial (UNITED) Presented by Suman Ghosh 🇨🇦 #RadOnc ☢️ @estroradiotherapy.bsky.social

031

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 De-intensification of postoperative radiotherapy in HNSCC by omitting contralateral elective neck irradiation– long term outcomes of the DIREKHT trial Presented by Charlotte Frei 🇩🇪 #RadOnc ☢️ @estroradiotherapy.bsky.social

021

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Paradigm shift from bilateral elective nodal irradiation to SPECT/CT-based SNP to guide unilateral irradiation in HNSCC: multicenter prospective study Presented by Abrahim Al-Mamgani🇳🇱

021

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Final results of a nationwide multicenter randomized trial (GOLD) on hypofractionated chemoradiation for glioblastoma: survival and HRQoL Presented by Anouk de Jong 🇳🇱 #RadOnc ☢️ @estroradiotherapy.bsky.social

021

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Patient-informed and data-driven cumulative toxicity score as an endpoint for clinical studies: Validation in a Phase III randomized trial (PARCER) Presented by Marta Pelizzola 🇩🇰 #RadOnc ☢️ @estroradiotherapy.bsky.social

021

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Five-year follow-up outcomes from JCOG1208: A single-arm confirmatory trial of IMRT alone for early-stage oropharyngeal cancer Presenter Satoaki Nakamura 🇯🇵

031

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Five-Year Follow-Up of the SABR 5 Trial: Primary Toxicity Analysis of Stereotactic Ablative Radiotherapy for Up to Five Oligometastases Presenter Robert Olson 🇨🇦

031

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Updated clinical outcomes from the RADIOSA randomized phase II trial Presented by Giulia Marvaso 🇮🇹 #RadOnc ☢️ @estroradiotherapy.bsky.social

021

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Eliminating surgery for breast cancers with an exceptional response to ablative radiotherapy: phase 2 trial primary endpoints Presented by Simona F. Shaitelman 🇺🇸 #RadOnc ☢️ @estroradiotherapy.bsky.social

031

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Long term results of radiation therapy de-escalation in cT1-2N1 breast cancer after primary systemic treatment (RAPCHEM, BOOG 2010-03; NCT01279304) Presented by Fleur Mauritz 🇳🇱 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 YO-HAI5 trial: 5- vs 15-fraction whole-breast irradiation with optional integrated boost: randomized phase III trial Presented by Renée De Noyette 🇧🇪 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Post-hoc analysis of metastasis-free survival (MFS) and Eugonadal MFS in the RADIOSA phase II randomized trial Presented by Giulia Marvaso 🇮🇹 #RadOnc ☢️ @estroradiotherapy.bsky.social

021

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Optimizing oligometastatic disease management with circulating tumor DNA: a correlative analysis from the phase II randomized EXTEND trial Presented by Alexander Sherry 🇺🇸 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Early Toxicity of elective nodal RT for Oligorecurrent Pelvic/Paraaortic nodes in Prostate Cancer: a randomised phase 3 trial OLIGOPELVIS-2/GETUG P12 Presenter Stéphane SUPIOT🇫🇷 #ProstateCancer

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Is a boost to the tumour bed still indicated after breast-conserving surgery and whole-breast radiotherapy in the era of modern systemic therapy? Presented by Femke Froklage 🇳🇱 #RadOnc ☢️ @estroradiotherapy.bsky.social

021

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Patterns of locoregional and distant recurrence and dosimetric analysis in the HypoG-01 phase III trial Presented by Louis Munschi 🇫🇷 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 OLIGOPELVIS 2-GETUG P12 elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial Presented by Hugo CORDA / Stéphane SUPIOT 🇫🇷 ☢️ #ProstateCancer @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Impact of AI-Avatar Based Digital Patient Engagement on Treatment Understanding, Empowerment and Stress in a US Community Radiation Oncology Practice Presented by Adam Raben 🇺🇸 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Status and practice of proton therapy for pregnant patients in Europe Presented by Maite Romero-Expósito 🇸🇪 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Final Results of the TROG 15.03 FASTRACK II Clinical Trial: Stereotactic Ablative Body Radiotherapy (SABR) for Primary Kidney Cancer by Shankar Siva 🇦🇺 #KidneyCancer

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Clinical and treatment characteristics associated with local control following SBRT: interim analysis of ESTRO EORTC E2-RADIatE OligoCare cohort Presented by Umberto Ricardi 🇮🇹 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Dose escalation with intraoperative radiotherapy in newly-diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised phase 3 trial Presented by Frank A. Giordano 🇩🇪 #RadOnc ☢️

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Internal Mammary and Medial Supraclavicular irradiation in stage I-III breast cancer: 20 years results of the randomised EORTC trial 22922/10925, including in pN0 patients Presenters Philip Poortmans 🇧🇪 & Orit Kaidar 🇮🇱 @estroradiotherapy.bsky.social

021

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 When less is not enough: first results from the phase III randomized DBCG RT Natural trial Presenter Birgitte Vrou Offersen 🇩🇰 #RadOnc @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 10-year Follow-Up of the DBCG HYPO Trial: Breast Induration, Recurrence and Survival After Hypofractionated Whole Breast Irradiation Presented by Hanna Forsberg 🇩🇰 #RadOnc ☢️ #BreastCancer @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Electron and brachytherapy boost after breast-conserving surgery and whole breast irradiation: 30-year results of the randomized Budapest Boost Trial Presented by Csaba Polgar 🇭🇺 #RadOnc ☢️ @estroradiotherapy.bsky.social

021

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Conventional vs Pelvic Ultra-Hypofractionated IMRT with HDR Brachytherapy in Prostate Cancer: Early Outcomes from PCS-XI Complete Cohort(NCT05820633) Presented by François Fabi 🇨🇦 #RadOnc ☢️ #ProstateCancer @estroradiotherapy.bsky.social

012

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Fifteen-year outcomes of the randomised APBI-IMRT Florence phase III trial of partial versus whole-breast irradiation in early #BreastCancer Presenter: Carlotta Becherini 🇮🇹

022

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Metastases-directed treatment in Patients with Oligometastatic Breast Cancer: Results from the OLIGOMA-trial (ARO-2021-09, NCT04495309) Presented by David Krug 🇩🇪 #RadOnc ☢️ @estroradiotherapy.bsky.social

022

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Ten-year results of the IMPORT HIGH trial (ISRCTN47437448): Dose escalated simultaneous integrated boost radiotherapy in early breast cancer Presented by Charlotte Coles 🇬🇧 #RadOnc ☢️ @estroradiotherapy.bsky.social

022

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Acute toxicity in PACE-NODES: A randomised trial of 5 fraction (f) prostate stereotactic body radiotherapy (SBRT) vs 5f prostate and pelvic nodal SBRT Presented by Angela Pathmanathan 🇬🇧 #RadOnc ☢️ #ProstateCancer @estroradiotherapy.bsky.social

012

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 DART: Darolutamide Added to Radiotherapy — A Randomised Phase II Trial of SBRT With or Without Darolutamide for Oligorecurrent Prostate Cancer Presenter Piet Ost 🇧🇪 #RadOnc @estroradiotherapy.bsky.social

012

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Towards objective cosmetic self-evaluation: machine-learning on photographs from breast conserving treatment with validation on external trial dataset Presented by Morten Sahlertz 🇩🇰 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward Trial Nodal Sub-study Presented by Saranya Ravindra 🇬🇧 #RadOnc ☢️ #BreastCancer @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Comparing Quality of Life (QOL) after adjuvant breast regional nodal radiotherapy (RNRT) within HYPORT Adjuvant trial (NCT03788213) Presented by SANJOY CHATTERJEE 🇮🇳 #RadOnc ☢️ @estroradiotherapy.bsky.social

033

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Salvage Hypofractionated Accelerated versus Standard Radiotherapy for Biochemical Recurrence after Radical Prostatectomy (SHARE): A Phase 3 Randomized Clinical Trial Presented by Youngju Song 🇰🇷 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I–III breast cancer #ESTRO26 acsjournals.onlinelibrary.wiley.com/doi/10.3322/...

022

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Long-Term Survival and Toxicity Outcomes in Over 1,200 Men Aged ≤60 Years Treated with LDR Brachytherapy Presented by William Hayhurst 🇬🇧 #RadOnc ☢️ @estroradiotherapy.bsky.social

011

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Side effects of moderately hypofractionated prostate and pelvic lymph node IMRT; results from the phase 3 PIVOTALboost randomised trial Presented by Isabel Syndikus 🇬🇧 #RadOnc ☢️ @estroradiotherapy.bsky.social

031

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

An Amazing Day 3 of #ESTRO26 KUDOS to Our friends at ESTRO for such an amazing meeting and looking forward to all that is to come in the following days. Amazing Stats coming from X ✅️ 14 million impressions (in 2025 Total ESTRO impressions 7,2 million) ✅️ 730 posts And so much more to come!!

032

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/05/2026

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Moderately fractionated prostate radiotherapy with a focal boost: acute and preliminary late side effects from the phase 3 PIVOTALboost trial Presented by Isabel Syndikus 🇬🇧 #RadOnc ☢️ @estroradiotherapy.bsky.social

032

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/05/2026

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Interim analysis of the EORTC ESTRO E2-Radiate 2011-RP ReCare cohort to assess adequacy of patient selection: Early death and adverse events after high-dose re-irradiation Presented by Nicolaus Andratschke 🇨🇭 #RadOnc ☢️ @estroradiotherapy.bsky.social

032

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/05/2026

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II) www.thelancet.com/journals/lan... FASTRACK II, the first phase 2 trial of stereotactic ablative body radiotherapy☢️ in #KidneyCancer #ESTRO26

022

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/05/2026

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Omission of elective nodal irradiation in HNSCC: long-term results and patient-level pooled analysis from 2 prospective trials (INRT-AIR & DARTBOARD) Presenter Sympascho Young 🇺🇸

032

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/05/2026

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Early regression index-guided dose escalation in locally advanced rectal cancer: long term results of the prospective THUNDER-2 trial Presented by Giuditta Chiloiro 🇮🇹 #RadOnc ☢️ @estroradiotherapy.bsky.social

022

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/05/2026

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Geographic accessibility of proton therapy services in Europe: current status and opportunities for enhancement Presenter Dominik Wawrzuta 🇵🇱

022

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/05/2026

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Prospectively validated biomarker signature for personalized radiooncology: Results of the DKTK-ROG HNprädBio biomarker trial for primary RCT of HNSCC Presenter Annett Linge 🇩🇪

022

Reposted by Ananya Choudhury

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/05/2026

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨 Best Physics Paper: Benchmarking synthetic computed tomography for radiotherapy from head to abdomen: SynthRAD2025 Grand Challenge report Presented by Matteo Maspero 🇳🇱 #RadOnc ☢️

022